Literature DB >> 33548010

Rho-kinase inhibitor hydroxyfasudil protects against HIV-1 Tat-induced dysfunction of tight junction and neprilysin/Aβ transfer receptor expression in mouse brain microvessels.

Qiangtang Chen1,2, Yu Wu1, Yachun Yu1, Junxiang Wei1, Wen Huang3.   

Abstract

HIV-1 transactivator protein (Tat) induces tight junction (TJ) dysfunction and amyloid-beta (Aβ) clearance dysfunction, contributing to the development and progression of HIV-1-associated neurocognitive disorder (HAND). The Rho/ROCK signaling pathway has protective effects on neurodegenerative disease. However, the underlying mechanisms of whether Rho/ROCK protects against HIV-1 Tat-caused dysfunction of TJ and neprilysin (NEP)/Aβ transfer receptor expression have not been elucidated. C57BL/6 mice were administered sterile saline (i.p., 100 μL) or Rho-kinase inhibitor hydroxyfasudil (HF) (i.p., 10 mg/kg) or HIV-1 Tat (i.v., 100 μg/kg) or HF 30 min before being exposed to HIV-1 Tat once a day for seven consecutive days. Evans Blue (EB) leakage was detected via spectrophotometer and brain slides in mouse brains. The protein and mRNA levels of zonula occludens-1 (ZO-1), occludin, NEP, receptor for advanced glycation end products (RAGE), and low-density lipoprotein receptor-related protein 1 (LRP1) in mouse brain microvessels were, respectively, analyzed by Western blotting and quantitative real-time polymerase chain reaction (qRT-PCR) analyses. Exposure of the mice to HIV-1 Tat increased the amount of EB leakage, EB fluorescence intensity, blood-brain barrier (BBB) permeability, as well as the RAGE protein and mRNA levels, and decreased the protein and mRNA levels of ZO-1, occludin, NEP, and LRP1 in mouse brain microvessels. However, these effects were weakened by Rho-kinase inhibitor HF. Taken together, these results provide information that the Rho/ROCK signaling pathway is involved in HIV-1 Tat-induced dysfunction of TJ and NEP/Aβ transfer receptor expression in the C57BL/6 mouse brain. These findings shed some light on potentiality of inhibiting Rho/Rock signaling pathway in handling HAND.

Entities:  

Keywords:  HIV-1 transactivator protein; Low-density lipoprotein receptor-related protein 1; Neprilysin; Receptor for advanced glycation end products; Rho/ROCK signaling pathway; Tight junction protein

Year:  2021        PMID: 33548010     DOI: 10.1007/s11010-021-04056-x

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  36 in total

1.  Selective CXCR4 antagonism by Tat: implications for in vivo expansion of coreceptor use by HIV-1.

Authors:  H Xiao; C Neuveut; H L Tiffany; M Benkirane; E A Rich; P M Murphy; K T Jeang
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-10       Impact factor: 11.205

Review 2.  The cerebral vasculature as a therapeutic target for neurological disorders and the role of shear stress in vascular homeostatis and pathophysiology.

Authors:  Ljiljana Krizanac-Bengez; Marc R Mayberg; Damir Janigro
Journal:  Neurol Res       Date:  2004-12       Impact factor: 2.448

3.  ZO-1 stabilizes the tight junction solute barrier through coupling to the perijunctional cytoskeleton.

Authors:  Christina M Van Itallie; Alan S Fanning; Arlene Bridges; James M Anderson
Journal:  Mol Biol Cell       Date:  2009-07-15       Impact factor: 4.138

4.  HIV-1 Tat protein mimicry of chemokines.

Authors:  A Albini; S Ferrini; R Benelli; S Sforzini; D Giunciuglio; M G Aluigi; A E Proudfoot; S Alouani; T N Wells; G Mariani; R L Rabin; J M Farber; D M Noonan
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-27       Impact factor: 11.205

5.  Complex phenotype of mice lacking occludin, a component of tight junction strands.

Authors:  M Saitou; M Furuse; H Sasaki; J D Schulzke; M Fromm; H Takano; T Noda; S Tsukita
Journal:  Mol Biol Cell       Date:  2000-12       Impact factor: 4.138

6.  Prevalence and pattern of neuropsychological impairment in human immunodeficiency virus-infected/acquired immunodeficiency syndrome (HIV/AIDS) patients across pre- and post-highly active antiretroviral therapy eras: a combined study of two cohorts.

Authors:  Lucette A Cysique; Paul Maruff; Bruce J Brew
Journal:  J Neurovirol       Date:  2004-12       Impact factor: 2.643

7.  PPARalpha and PPARgamma attenuate HIV-induced dysregulation of tight junction proteins by modulations of matrix metalloproteinase and proteasome activities.

Authors:  Wen Huang; Sung Yong Eum; Ibolya E András; Bernhard Hennig; Michal Toborek
Journal:  FASEB J       Date:  2009-01-13       Impact factor: 5.191

8.  Caveolin-1 regulates human immunodeficiency virus-1 Tat-induced alterations of tight junction protein expression via modulation of the Ras signaling.

Authors:  Yu Zhong; Eric J Smart; Babette Weksler; Pierre-Olivier Couraud; Bernhard Hennig; Michal Toborek
Journal:  J Neurosci       Date:  2008-07-30       Impact factor: 6.167

Review 9.  The comorbidity of HIV-associated neurocognitive disorders and Alzheimer's disease: a foreseeable medical challenge in post-HAART era.

Authors:  Jiqing Xu; Tsuneya Ikezu
Journal:  J Neuroimmune Pharmacol       Date:  2008-11-19       Impact factor: 4.147

10.  Neurocognitive change in the era of HIV combination antiretroviral therapy: the longitudinal CHARTER study.

Authors:  Robert K Heaton; Donald R Franklin; Reena Deutsch; Scott Letendre; Ronald J Ellis; Kaitlin Casaletto; Maria J Marquine; Steven P Woods; Florin Vaida; J Hampton Atkinson; Thomas D Marcotte; J Allen McCutchan; Ann C Collier; Christina M Marra; David B Clifford; Benjamin B Gelman; Ned Sacktor; Susan Morgello; David M Simpson; Ian Abramson; Anthony C Gamst; Christine Fennema-Notestine; David M Smith; Igor Grant
Journal:  Clin Infect Dis       Date:  2014-10-31       Impact factor: 20.999

View more
  1 in total

1.  Intraneuronal β-Amyloid Accumulation: Aging HIV-1 Human and HIV-1 Transgenic Rat Brain.

Authors:  Hailong Li; Kristen A McLaurin; Charles F Mactutus; Benjamin Likins; Wenfei Huang; Sulie L Chang; Rosemarie M Booze
Journal:  Viruses       Date:  2022-06-10       Impact factor: 5.818

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.